Expression of Delta-catenin protein in breast invasive ductal carcinoma and relationship between its expression and prognosis of patients

孙丽红; 康慧卿; 王霞

doi:10.3969/j.issn.1007-3969.2015.06.002

您当前的位置：

首页 >

文章列表页 >

Expression of Delta-catenin protein in breast invasive ductal carcinoma and relationship between its expression and prognosis of patients

更新时间：2025-12-31

- Expression of Delta-catenin protein in breast invasive ductal carcinoma and relationship between its expression and prognosis of patients
- China Oncology Vol. 25, Issue 6, Pages: 409-415(2015)
- 作者机构：
  
  1. 赤峰学院附属医院检验科,内蒙古,赤峰,024000
  2. 乌海市人民医院病理科,内蒙古,乌海,016000
  3. 乌海市人民医院神经内科,内蒙古,乌海,016000
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.06.002
  CLC：
- Published Online：14 August 2015，
  
  Published：14 August 2015
- 稿件说明：
移动端阅览
孙丽红,康慧卿,王霞,等. Delta-catenin蛋白在乳腺浸润性导管癌中的表达及其与患者预后的关系[J]. 中国癌症杂志, 2015, 25(6): 409-415.

孙丽红, 康慧卿, 王霞. Expression of Delta-catenin protein in breast invasive ductal carcinoma and relationship between its expression and prognosis of patients[J]. China Oncology, 2015, 25(6): 409-415.
孙丽红,康慧卿,王霞,等. Delta-catenin蛋白在乳腺浸润性导管癌中的表达及其与患者预后的关系[J]. 中国癌症杂志, 2015, 25(6): 409-415. DOI： 10.3969/j.issn.1007-3969.2015.06.002.

孙丽红, 康慧卿, 王霞. Expression of Delta-catenin protein in breast invasive ductal carcinoma and relationship between its expression and prognosis of patients[J]. China Oncology, 2015, 25(6): 409-415. DOI： 10.3969/j.issn.1007-3969.2015.06.002.

摘要

背景与目的：作为黏附分子Catenin家族中的一员，Delta-catenin蛋白在众多肿瘤中的表达意义及作用机制尚未明确。该研究探讨了Delta-catenin在乳腺癌中的表达情况及其与患者预后的关系。方法：应用免疫组化检测92例乳腺癌组织芯片中Delta-catenin的表达及其与患者临床病理因素之间的关系。另选32例冻存的乳腺癌及癌旁正常乳腺组织用于Delta-catenin的mRNA和蛋白检测。结果：与正常乳腺组织相比，Delta-catenin的mRNA和蛋白在乳腺癌组织中表达显著增高，且Delta-catenin的表达与乳腺癌的组织学分级及淋巴结转移密切相关(P=0.016，P=0.022)。此外，Kaplan-Meier生存曲线揭示Delta-catenin高表达的患者生存时间显著短于低表达的患者(P=0.015)，同时Cox多变量分析显示Delta-catenin高表达也是判断患者预后的独立危险因素(P=0.017)。结论：作为一个癌蛋白，Delta-catenin在乳腺癌组织中的高表达与患者的不良预后显著相关。

Abstract

Background and purpose: As a member of Catenin family

little is known about expressive significance and mechanism of Delta-catenin in numerous tumors. In present study

we investigated the expression of Delta-catenin in breast cancer tissues and its correlation with the prognosis of patients. Methods: We examined the expression of Delta-catenin and its correlation with clinicopathological factors of patients by immunohistochemistry in 92 cases of breast cancer tissues with tissue micro-array. The mRNA and protein expression of Delta-catenin were also detected in another 32 cases of frozen paired breast cancer tissues and normal breast tissues. Results: Compared with normal breast tissues

the mRNA and protein expression of Delta-catenin were increased in breast cancer tissues

and expression of Delta-catenin was closely associated with histological grade and lymph node metastasis (P=0.016 and 0.022

respectively). Moreover

Kaplan-Meier survival analysis revealed that patients with high Delta-catenin expression had shorter survival than patients with low expression (P=0.015)

and multivariate Cox analysis revealed that high Delta-catenin expression was also an independent prognostic factor (P=0.017). Conclusion: Our results suggest that Delta-catenin acts as an oncoprotein when overexpressed in breast cancer

and its expression is associated with poor prognosis of patients.

关键词

Keywords

references

Views

1355

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on the association of breast cancer patients’ prognosis with internal mammary sentinel lymph node biopsy

Receptor discordance between primary breast cancer and liver metastases

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study

Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation

Research progress and prospects of neoadjuvant endocrine therapy for breast cancer

Related Author

Ruijie JIA

Zhiqiang SHI

Qi ZHANG

Yongjin LU

Junsheng ZHENG

Jing SUN

Zhao BI

Xiao SUN

Related Institution

Shandong First Medical University Affiliated Tumor Hospital (Shandong Provincial Institute of Cancer Prevention and Treatment, Shandong Cancer Hospital)

Shandong First Medical University (Shandong Provincial Academy of Medical Sciences)

Tianjin Medical University Cancer Institute and Hospital

Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰